ICU
NASDAQSeaStar Medical Holding Corporation
News25/Ratings0
News · 26 weeks46+300%
2026-04-262026-10-18
Mix1690d
- Other9(56%)
- SEC Filings5(31%)
- Earnings1(6%)
- Insider1(6%)
Latest news
25 items- PRSeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology AwardAward recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support Keynote presentation and award ceremony to occur at Update in Critical Care Nephrology 2026 DENVER, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Chief Medical Officer Col. (Ret.) Kevin Chung, MD, MACP, FCCM, has been recognized as the 2026 recipient of the Combat Nephrology Award at the Update in
- SECSEC Form D filed by SeaStar Medical Holding CorporationD - SeaStar Medical Holding Corp (0001831868) (Filer)
- PRFDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic ConditionPotentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic
- SECSEC Form 8-K filed by SeaStar Medical Holding Corporation8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
- PRSeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross ProceedsDENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 854,002 shares of SeaStar Medical’s common stock, originally issued in June 2025, July 2025 and August 2025 (collectively, the "Prior Warrants"), having exercise prices ranging from $6.38 to $7.62 per share, at a reduced exercise price of $3.866 per share, for aggrega
- PRSeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026. Presentation Details: Title: Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatr
- PRNew ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced that effective today, October 1, 2026, new ICD-10-PCS codes are available to enable administrative, billing, and statistical reporting for the use of SeaStar Medical’s SCD therapy
- PRSeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI) DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Chief Medical Officer, Kevin Chung, M.D., will deliver an invited talk at the 2026 PPETS conference, hosted by Texas Children’s Hospital in Houston, Texas, October 6 - 8, 2026. The annual PPETS conference gathers leading international pediatric nephrolo
- PRSeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD TherapyPrestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critically ill pediatric patients with acute kidney injury (AKI) SeaStar Medical’s SCD development pipeline of indications holds promise for multiple additional indications DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that H. David Humes, M.D., is being awarded this year’s Distinguished University Innovato
- PRSeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment ConferenceDENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City. The SeaStar Medical presentation will be available on September 11, 2026, at 7:00 am Eastern Time and can be accessed by visiting the Events & Presentations page, located under the Investor Relations section of the SeaStar Medic
- INSIDERChief Financial Officer Messinger Michael bought $2,452 worth of shares (750 units at $3.27), increasing direct ownership by 43% to 2,500 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- SECSEC Form 10-Q filed by SeaStar Medical Holding Corporation10-Q - SeaStar Medical Holding Corp (0001831868) (Filer)
- SECSeaStar Medical Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
- PRSeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAdded 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Obtained ICD-10-PCS codes to enable standardized inpatient hospital billing for its selective cytopheretic device (SCD) therapy, including QUELIMMUNE Webcast today at 4:30 pm Eastern Time DENVER, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of
- PRSeaStar Medical to Report Second Quarter Financial Results on August 12, 2026DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its second quarter financial results after market close on Wednesday, August 12, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, August 12, 2026, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Register for the call:Preregistration is required to attend the live call and can be accessed here. A pin code
- SECSEC Form S-8 filed by SeaStar Medical Holding CorporationS-8 - SeaStar Medical Holding Corp (0001831868) (Filer)
- PRSeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that it is a proud sponsor of key initiatives to advance the treatment of pediatric patients with acute kidney injury (AKI). AKI is a major driver of critical illness, prolonged hospital stays, and high mortality rates. Despite its massive impact on patient outcomes, significant gap
- INSIDERChief Executive Officer Schlorff Eric was granted 10,288 shares, increasing direct ownership by 26% to 50,140 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERChief Medical Officer Chung Kevin was granted 7,202 shares, increasing direct ownership by 35% to 28,021 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERDirector Vincent Bernadette N was granted 4,000 shares, increasing direct ownership by 95% to 8,200 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERDirector Neuman John was granted 4,000 shares, increasing direct ownership by 33% to 16,200 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERDirector Van Heel Kenneth was granted 4,000 shares, increasing direct ownership by 50% to 11,940 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- INSIDERDirector Baird Jennifer A was granted 4,000 shares, increasing direct ownership by 60% to 10,620 units (SEC Form 4)4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
- SECSeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
- SECAmendment: SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update8-K/A - SeaStar Medical Holding Corp (0001831868) (Filer)
ICU FAQ
5 questionsWhere does ICU stock trade?
SeaStar Medical Holding Corporation (ICU) is listed on NASDAQ.What sector and industry is ICU in?
SeaStar Medical Holding Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did SeaStar Medical Holding Corporation go public?
SeaStar Medical Holding Corporation (ICU) completed its IPO in 2021.What companies are similar to ICU?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare ICU side-by-side with any of them on Quantisnow.How can I track ICU on Quantisnow?
Quantisnow aggregates SeaStar Medical Holding Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ICU to receive live email and push alerts on every new disclosure.